繁體中文
English
PharmaEssentia US
PharmaEssentia Japan
Panco
PharmaEssentia-Ropeginterferon alfa-2b,P1101,PV,polycythemia vera,new drug development,biologics,PIC/s GMP protein plant>
Mobile Button
Search>
About Us
Achievements
Executives
Corporate Governance Structure
Board of Directors
Partnership
Join Us
Locations
Privacy and Cookies Policy
Capabilities
R&D Center
Pipeline
Core Technology
R&D Focus
Manufacturing Site
Milestone
Facilities
Process and Critical Equipment
Focus
Hematology
P1101 in ET Phase III
Infectious Diseases
Clinical Study of P1101 in treatment of Chronic Hepatitis B
P1101 in HCV Phase III in Genotype 2 Study (A14-301)
Oncology
KX-ORAX-005 Oraxol in combination with Ramucirumab for Gastric, Gastro-esophageal or Esophageal Cancer
KX-ORAX-007 A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
PD-1 in HCC Phase I/II (IIT)
Dermatology
KX01 in Psoriasis
Resources
Patients & Healthcare
Patients & Healthcare Professionals
Medical Information
News
Latest News
Press Releases
Events
Investors
Financial Information
Shareholder’s Services
FAQ
Events & Presentations
Contact Us
ESG
Downloads
Downloads and Interactions
Contact
Language
繁體中文
English
日本語
Subsidiary
PharmaEssentia US
PharmaEssentia Japan
Panco
Ropeginterferon alfa-2b
The predominantly single isomer long acting interferon alpha-2b
Development Pipeline
Press Releases
pharmaessentia